Ilika plc grants options under the Long Term Incentive Plan

Ilika

Ilika Plc (LON:IKA), a pioneer in solid-state battery technology, has announced that on 28 February 2023 it granted options to Executive Directors and employees under the Long Term Incentive Plan approved by shareholders in 2018 and the EMI scheme.

LTIP

Ilika awarded nominal value options under the LTIP over 416,954 ordinary shares of 1p each in the Company to an Executive Director and options over a further 2,800 Ordinary Shares to employees. Each award vests on the achievement of certain performance targets over a three-year period. 

EMI option scheme

Ilika plc granted market value options over 802,248 ordinary shares of 1p each in the Company to an Executive Director and employees under the Company EMI option scheme.  EMI options vest on the achievement of certain performance targets over a three-year period. 

The awards are intended to align the incentives of the Executive Directors and other senior employees with the Company’s performance and outcomes for shareholders over the long term and to provide effective and attractive levels of reward, based on delivering strong performance in a fair and proportionate manner.

In total, options over 1,222,002 Ordinary Shares have been granted representing 0.77% of issued share capital.

Details of grants issued under the LTIP and EMI option scheme by each Executive Director are set out in the table below, together with the total number of Ordinary Shares each Executive Director holds under option and is interested in.

DirectorNumber of options grantedScheme under which options grantedTotal number of Options now heldPer cent. of issued share capital
Graeme Purdy416,954LTIP2,779,0671.76
Jason Stewart300,000EMI300,0000.19

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ilika’s Stereax batteries set for Medical Technology Ireland showcase

Ilika’s Stereax batteries will be showcased by Cirtec Medical at Medical Technology Ireland, giving the company targeted exposure in the medical device market.

Ilika CEO Graeme Purdy discusses Stereax revenues and Goliath opportunities

Ilika CEO Graeme Purdy discusses first Stereax revenues, grant support for Goliath, EV market trends, and opportunities in defence and e-bikes.

Ilika positions solid state batteries for the future of implantable neurostimulation

Ilika’s Stereax solid state battery technology supports the development of smaller, safer and more practical implantable neurostimulation devices for emerging medical applications.

Ilika advances manufacturing readiness for solid-state batteries

Ilika’s collaboration with UKBIC shows how manufacturing validation is helping move its Goliath pouch cell technology closer to commercial readiness.

Ilika reports first Stereax revenues and Goliath progress

Ilika expects FY26 revenue of approximately ÂŁ1.1m, including first commercial Stereax electrode sales, with Goliath evaluation activity expanding across automotive, defence and e-bike applications.

Search